Novatek Pharmaceuticals

Novatek Pharmaceuticals is a company with a renowned team leading clinical investigations focused on development of immunomodulatory drugs related to cancers and infectious diseases. Empowering naturally derived immunotherapy that is effective across various cancer types, with the goal of effectively boosting the immune system and T cell population in patients while reducing the adverse effects of disease or cytotoxic therapies. We primarily work with Nigella Sativa (Black seeds) a natural derivative incorporated within our proprietary drug NP-101. Clinical trials conducted in 2021 demonstrated that NP-101 has applications for immunotherapy and cancer treatment showcasing significant effect on T cells. The Novatek team has 100+ years of clinical research and pharmaceutical development experience, resulting in 400+ peer reviewed publications and a strong pharmaceutical pipeline.